Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pivotal Study of the FRED Stent System in the Treatment of Intracranial Aneurysms (FRED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01801007
Recruitment Status : Completed
First Posted : February 28, 2013
Results First Posted : October 9, 2020
Last Update Posted : March 8, 2021
Sponsor:
Information provided by (Responsible Party):
Microvention-Terumo, Inc.

Brief Summary:
The purpose of this study is to evaluate the safety and effectiveness of the MicroVention Flow Redirection Intraluminal Device (FRED) system when used in the treatment of wide-necked intracranial aneurysms.

Condition or disease Intervention/treatment Phase
Intracranial Aneurysms Device: Flow Re-Direction Endoluminal Device (FRED) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 145 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: FRED
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pivotal Study of the MicroVention Flow Re-Direction Endoluminal Device (FRED) Stent System in the Treatment of Intracranial Aneurysms
Study Start Date : July 2013
Actual Primary Completion Date : January 2018
Actual Study Completion Date : January 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Flow Re-Direction Endoluminal Device Device: Flow Re-Direction Endoluminal Device (FRED)



Primary Outcome Measures :
  1. Percentage of Participants With Complete Occlusion of the Target Aneurysm and ≤50% Stenosis of the Parent Artery and an Alternative Treatment of the Target Intracranial Aneurysm (IA) Had Not Been Performed Within 12 Months [ Time Frame: 12 months ]
    The primary effectiveness endpoint has three components: 1) complete occlusion of the target aneurysm assessed by a core laboratory utilizing the Raymond-Roy Scale 2) ≤ 50% stenosis of the parent artery at the target (IA) using the Warfarin-Aspirin Symptomatic Intracranial Disease(WASID) criterion which is defined as greater than 50% luminal loss, 3) alternative treatment of the target IA is defined as re-treatment of the target aneurysm with an alternative treatment modality including open repair, endovascular placement of an additional stent or treatment of In-stent Stenosis observed. The Raymond-Roy Occlusion Classification has 3 responses, where Grade I is complete occlusion, no flow of contrast seen in the sac, Grade II is partial occlusion, some flow in the neck or sac, and Grade III is incomplete occlusion, apparent flow into the sac. Grade 1 indicates the best outcome.

  2. Percentage of Participants Who Experience Neurological Death or Major Ipsilateral Stroke Measured by the Modified Rankin Scale (mRS) and the National Institute of Health Stroke Scale (NIHSS) [ Time Frame: 12 months ]
    A major stroke is defined as a new neurological event that persists for > 24 hours and results in a ≥ 4 points increase in the NIHSS score compared to baseline or compared to any subsequent lower score. A major ipsilateral stroke is defined as that occurring within the vascular distribution of the stented artery. Neurologic death is defined as a death which has been adjudicated by the independent clinical events committee to have directly resulted from a neurologic cause.The NIHSS score ranges from 0 (no stroke symptoms) to 42 (severe stroke). mRS is 6 point assessment scale used to assess disability in patients who have suffered a stroke and is compared over time to check for recovery and degree of continued disability. The mRS score ranges from 0 (no disability) to 6 (death).


Secondary Outcome Measures :
  1. Percentage of Participants With Complete Occlusion of the Target Aneurysm on 12-month Angiography (Raymond-Roy 1) [ Time Frame: 12 months ]
    Complete occlusion of the target aneurysm assessed by a core laboratory. The Raymond-Roy class is an angiographic classification scheme for grading the occlusion (closure) of endovascularly treated intracranial aneurysms: class I: complete obliteration, class II: residual neck, class III: residual aneurysm.

  2. Percentage of Participants With ≥ 50% In-Stent Stenosis (ISS) at the Target Intracranial Aneurysm (IA) at 12 Months as Assessed by Angiography at the Independent Core Laboratory [ Time Frame: 12 months ]
    Stenosis of the parent artery at the target IA using the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) criterion which is defined as greater than 50% luminal loss

  3. Percentage of Participants in Whom an Unplanned Alternative Treatment of the Target IA Had Not Been Performed Within 12 Months [ Time Frame: 12 months ]
    Re-treatment of the target aneurysm with an alternative treatment modality including open repair, endovascular placement of an additional stent or treatment of In-stent Stenosis observed

  4. Percentage of Participants With Clinically Acceptable (90-100%) Occlusion of the Target Aneurysm, ≤ 50% Stenosis of the Parent Artery at the Target IA, and an Unplanned Alternative Treatment of the Target IA Had Not Been Performed [ Time Frame: 12 months ]
    This endpoint has three components: 1) clinically acceptable occlusion of the target aneurysm assessed by a core laboratory as percent occlusion (90%-100%) 2) ≤ 50% stenosis of the parent artery at the target IA using the WASID criterion which is defined as greater than 50% luminal loss, 3) alternative treatment of the target IA is defined as re-treatment of the target aneurysm with an alternative treatment modality including open repair, endovascular placement of an additional stent or treatment of In-stent Stenosis observed. The Raymond-Roy scale has 3 responses, where Grade I is complete occlusion, no flow of contrast seen in the sac, Grade II is partial occlusion, some flow in the neck or sac, and Grade III is incomplete occlusion, apparent flow into the sac.

  5. Percentage of Participants With Unsuccessful Delivery of the FRED [ Time Frame: Index Procedure ]
    Inability to deliver a FRED device to the target location

  6. Percentage of Participants That Had Procedure Related Serious Adverse Events With the FRED System [ Time Frame: 12 months ]
    A serious adverse event is any medical experience regardless of its relationship to the study treatment that occurs during participant enrollment in this trial that results in any of the following: (1) inpatient hospitalization or prolongation of a hospitalization; (b) persistent or significant disability or incapacity; (c) death of the study participant, or (d) necessitates an intervention to prevent a permanent impairment of a body function or permanent damage to a body structure. Procedure related events were associated with the index procedure, antiplatelet therapy, or follow up angiography.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant whose age ≥ 22 and ≤75 years
  • Participant has single target aneurysm located in the internal carotid artery
  • Participant sign and date an IRB/EC approved informed consent prior initiation of any study procedures

Exclusion Criteria:

  • Participant who suffers from an intracranial hemorrhage in the last 30 days
  • Participant who suffers from a subarachnoid hemorrhage in the last 60 days
  • Participant with symptomatic extracranial mass or currently undergoing radiation therapy for tumor of the head and neck region
  • Participant who is pregnant or breastfeeding
  • Participant has an arteriovenous malformation (AVM) in the area of the target aneurysm

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01801007


Locations
Show Show 24 study locations
Sponsors and Collaborators
Microvention-Terumo, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Cameron McDougall, MD Johns Hopkins University
  Study Documents (Full-Text)

Documents provided by Microvention-Terumo, Inc.:
Statistical Analysis Plan  [PDF] July 13, 2018
Study Protocol  [PDF] November 14, 2016

Layout table for additonal information
Responsible Party: Microvention-Terumo, Inc.
ClinicalTrials.gov Identifier: NCT01801007    
Other Study ID Numbers: CL12001
G120111 ( Other Identifier: FDA )
First Posted: February 28, 2013    Key Record Dates
Results First Posted: October 9, 2020
Last Update Posted: March 8, 2021
Last Verified: February 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Intracranial Aneurysm
Aneurysm
Vascular Diseases
Cardiovascular Diseases
Intracranial Arterial Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases